Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2029

Conditions
AmeloblastomaBRAF V600E Mutation Positive
Interventions
DRUG

Dabrafenib

"Dosage: 150 mg orally, twice daily (total daily dose of 300 mg) Administration: Administer at approximately 12 hours apart. Take at the same time each day. If a dose is missed and less than 6 hours remain until the next dose, skip the missed dose. Do not open, crush, or break the capsules.~Usage in Combination: When used in combination with trametinib, trametinib should be taken once daily at the same time as either the morning or evening dose of dabrafenib to ensure synchronization of the treatment schedule."

DRUG

Trametinib

"Dosage: 2 mg orally, once daily Administration: Administer at least 1 hour before or 2 hours after a meal. Take at the same time each day. If a dose is missed, it should be taken no later than 12 hours before the next scheduled dose; otherwise, skip the missed dose.~Usage in Combination: When used in combination with trametinib, trametinib should be taken once daily at the same time as either the morning or evening dose of dabrafenib to ensure synchronization of the treatment schedule."

Trial Locations (1)

200011

RECRUITING

Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors
lead

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

OTHER